You searched for "Ocular"
My Top Five: Promising gene therapies for ocular conditions
Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...My Top Five: Promising gene therapies for ocular conditions
Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...
How does teprotumumab impact on ocular misalignment in thyroid eye disease?
A retrospective case review was conducted with the aim of exploring the effect of teprotumumab on objective diplopia. Adults diagnosed with thyroid eye disease, presenting with diplopia and receiving a standard six-month treatment with teprotumumab at a single centre were...Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...Reichert Ocular Response Analyser G3
Make a more confident glaucoma risk assessment with Corneal Hysteresis. ORA® G3 is the only tonometer that measures Corneal Hysteresis (CH), a superior predictor of glaucoma progression. CH is an indication of the biomechanical properties of the cornea differing from...
Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience
Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases
This is a retrospective study of patients with ocular surface inflammatory diseases (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease),...
Low dose steroids for ocular dry eye disease in graft vs. host disease
This double-masked randomised clinical trial compared the response of dry eye disease (DED) to treatment with topical steroids in patients with and without graft vs. host disease (GVHD). Forty-two patients in a single centre (n=21 with and n=21 without GVHD)...
Changes in ocular biomarkers in Vogt-Koyanagi-Harada disease after pulse steroid therapy
This retrospective study aimed to evaluate the early and chronological changes in ocular biomarkers in patients of Vogt Koyanagi Harada (VKH) disease who received pulse steroid therapy. It further aimed to identify which biomarkers correlated with the best corrected visual...
Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant
This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...Understanding spaceflight-associated neuro-ocular syndrome (SANS): what do we know?
Introduction Formerly known as visual impairment and intracranial pressure syndrome (VIIP), space-related neuro-ocular syndrome (SANS) is defined by a collection of ophthalmic and neurological findings in astronauts after long-term spaceflight [1]. Changes in the eyeball, such as hyperopic shift, during...
